mHealth Medication Safety Intervention

Improving Transplant Medication Safety Through A Pharmacist-Empowered, Patient-Centered, Mhealth-Based Intervention (TRANSAFE Rx Study)

TRANSAFE Rx is a 12-month, parallel two-arm, 1:1 randomized controlled clinical trial, involving 136 participants (68 in each arm) measuring the clinical and economic effectiveness of a pharmacist-led intervention, which utilizes an innovative mHealth application to improve medication safety and health outcomes, as compared to usual post-transplant care. The primary goal of the TRANSAFE Rx study is to demonstrate significant reductions in med safety issues leading to reduced healthcare resource utilization in kidney transplantation through a pharmacist-led, mHealth-enabled, intervention. This study will provide detailed and novel information on the incidence, etiologies and outcomes of med errors and adverse drug events in this high-risk population; while also demonstrating the effectiveness of this intervention on reducing the incidence and impact of med safety issues in kidney transplantation.

Inclusion Criteria:

• Kidney transplant recipient between 6 and 36 months post-transplant
• At least 18 years of age
• Transplant MD agrees that patient is eligible to participate

Exclusion Criteria:

• Multi-organ recipient
• Patient is incapable of:
• Measuring their own blood pressure and glucose (if applicable)
• Self-administering medications
• Speaking, hearing and reading English
• Utilizing the mHealth application, after training